SRR27320682
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 75.91666667
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.410
- G2M_CHECKPOINT+0.390
- E2F_TARGETS+0.380
- MYC_TARGETS_V1+0.270
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.250
- APICAL_SURFACE+0.220
- MITOTIC_SPINDLE+0.220
- TGF_BETA_SIGNALING+0.180
- MYC_TARGETS_V2+0.170
- FATTY_ACID_METABOLISM+0.150
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.550
- INTERFERON_GAMMA_RESPONSE-0.470
- ALLOGRAFT_REJECTION-0.460
- TNFA_SIGNALING_VIA_NFKB-0.460
- INFLAMMATORY_RESPONSE-0.450
- INTERFERON_ALPHA_RESPONSE-0.430
- COMPLEMENT-0.350
- IL2_STAT5_SIGNALING-0.320
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.220
- KRAS_SIGNALING_UP-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-77-8128-01A-11R-2247-07 | — | cohortSQ2 | 0.843 |
| 2 | X97abcebb.f885.4eca.9af4.91a0adb97578 | — | cohortMD1 | 0.836 |
| 3 | MNG142 | — | — | 0.826 |
| 4 | TCGA-51-4081-01A-01R-1100-07 | — | cohortSQ2 | 0.821 |
| 5 | 7478db87-0751-4771-941f-9fccdf01853d | — | — | 0.811 |
| 6 | AUR-AD9E-TTM1-A-1-1-R-A542-39 | — | B | 0.806 |
| 7 | MDT-AP-1330 | Med | Medulloblastoma | 0.797 |
| 8 | SRR8392888 | — | cohortMD1 | 0.795 |
| 9 | TCGA-43-7657-01A-31R-2125-07 | — | cohortSQ1 | 0.793 |
| 10 | TCGA-CV-6940-01A-11R-1915-07 | — | — | 0.790 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.410 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.390 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.380 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.270 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.250 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.220 | Temsirolimus | — uncovered |
| MITOTIC_SPINDLE | 0.220 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.180 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.170 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.140 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.140 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| PEROXISOME | 0.100 | Idelalisib | — uncovered |
| MYOGENESIS | 0.080 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.070 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.040 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.030 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.020 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.020 | Inavolisib | — uncovered |